Emily A. Pace
Impact in
-
- NF-κB Signaling Pathways
- Oncology top 10%
- HER2/EGFR in Cancer Research
Papers in
-
- Natural product bioactivities and synthesis 2
- PI3K/AKT/mTOR signaling in cancer 2
- Metabolism, Diabetes, and Cancer 1
- Oncology 5
- HER2/EGFR in Cancer Research 3
- Co-authors
- Thomas D. Gilmore (5 shared papers)Mei‐Chih Liang (5 shared papers)John A. Porco (5 shared papers)Peter K. Sorger (3 shared papers)Birgit Schoeberl (4 shared papers)Sujata Bardhan (3 shared papers)Chaomin Li (4 shared papers)Kevin A. Janes (1 shared paper)
- Journals
- Science Signaling (2 papers)Clinical Cancer Research (1 paper)BMC Biology (1 paper)Journal of the American Chemical Society (1 paper)Organic Letters (1 paper)
- Partner nations
- United States
In The Last Decade
Emily A. Pace
10 papers receiving 758 citations
Peers
Comparison fields: 5 of 76
- Cancer Research 143
- Oncology 233
- Toxicology 29
- Molecular Biology 501
- Computational Theory and Mathematics 112
Countries citing papers authored by Emily A. Pace
This map shows the geographic impact of Emily A. Pace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily A. Pace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily A. Pace more than expected).
Fields of papers citing papers by Emily A. Pace
This network shows the impact of papers produced by Emily A. Pace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily A. Pace. The network helps show where Emily A. Pace may publish in the future.
Co-authors
The 25 scholars most cited alongside Emily A. Pace, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 275 | |
| 2 | 2005 | 124 | |
| 3 | 2005 | 76 | |
| 4 | 2013 | 73 | |
| 5 | 2002 | 64 | |
| 6 | 2001 | 47 | |
| 7 | 2018 | 44 | |
| 8 | 2003 | 40 | |
| 9 | 2014 | 32 | |
| 10 | 2002 | 2 | |
| 11 | 2023 | 0 |
About Emily A. Pace
Emily A. Pace is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Cancer Research and Pharmacology, having authored 11 papers that have together received 777 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (3 papers), NF-κB Signaling Pathways (3 papers), Computational Drug Discovery Methods (2 papers), Natural product bioactivities and synthesis (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Inflammatory mediators and NSAID effects (2 papers), Organic Chemistry Cycloaddition Reactions (1 paper) and Metabolism, Diabetes, and Cancer (1 paper). The work is most often cited by research in Cancer Research (143 citations), Oncology (233 citations), Toxicology (29 citations), Molecular Biology (501 citations) and Computational Theory and Mathematics (112 citations). Emily A. Pace has collaborated with scholars based in United States. Frequent co-authors include Thomas D. Gilmore, Mei‐Chih Liang, John A. Porco, Peter K. Sorger, Birgit Schoeberl, Sujata Bardhan, Chaomin Li, Kevin A. Janes, John G. Albeck and Douglas A. Lauffenburger. Their work appears in journals such as Science Signaling, Clinical Cancer Research, BMC Biology, Journal of the American Chemical Society and Organic Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.